智通财经APP讯，赛生药业(06600)发布公告，于2024年5月29日，要约人Silver Pegasus Investment Limited接获Pentwater Capital Management Europe LLP(Pentwater)就2925万股股份(分别占于本公告日期的本公司已发行股本约4.64%及无利害关系股东持有的本公司已发行股本约8.51%，且为Pentwater于本公告日期持有的所有股份)发出的无约束力支持函件(无约束力支持函件)，确认其拟就将于法院会议及股东特别大会上提呈的决议案投赞成票，以批准及实施建议、计划及存续安排。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.